UnitedHealth Group stock holds near 400 USD as Q2 2026 earnings beat and guidance support valuation

UnitedHealth Group stock is trading close to 400 USD as investors digest a strong Q2 2026 earnings beat and a full year guidance range of 19.50 to 20.00 USD per share, with the valuation near 20 times the midpoint of management’s outlook.

UnitedHealth Group stock (ISIN US91324P1021) is trading close to 400 USD per share, with a latest closing price of 399.67 USD on the New York Stock Exchange as of September 2, 2026, according to market data compiled by MarketBeat. The valuation stands near 20 times the midpoint of the company’s 2026 adjusted earnings per share guidance, a level many investors view as supported by recent quarterly results.

Q2 2026 earnings beat underpins guidance

According to an instant alert overview on MarketBeat, UnitedHealth Group reported adjusted earnings of 6.38 USD per share for its most recent quarter, compared with analysts’ consensus estimates of 4.94 USD. This represents an earnings beat of 1.44 USD per share in the quarter, or roughly 29 percent above the consensus figure for the period, highlighting strong profitability in the managed care and health services businesses in Q2 2026.

The same MarketBeat summary states that UnitedHealth Group generated quarterly revenue of 112.03 billion USD, versus a consensus expectation of 110.81 billion USD for the same reporting period. While the revenue beat of about 1.22 billion USD is more modest in percentage terms than the earnings surprise, it still points to resilient top line growth in the second quarter of 2026. MarketBeat notes that revenue for the quarter was up about 0.4 percent compared with the same quarter in the prior year, illustrating that most of the earnings improvement stems from margin and mix rather than rapid revenue expansion.

Full year 2026 guidance and analyst view

On the back of these figures, UnitedHealth Group has set its fiscal year 2026 guidance for adjusted earnings per share in a range of 19.50 to 20.00 USD, according to the same MarketBeat coverage. Using the midpoint of 19.75 USD, this implies that the latest closing price of 399.67 USD as of September 2, 2026 equates to a forward price to earnings multiple of roughly 20 times, a valuation investors often associate with companies that have relatively predictable earnings and strong cash generation.

MarketBeat’s consensus overview indicates that sell side analysts forecast an average adjusted earnings per share of about 19.82 USD for UnitedHealth Group in 2026, essentially in line with management’s guidance range. In addition, the data show a consensus rating described as Moderate Buy, together with an average analyst price target around 456.56 USD per share. This target sits more than 14 percent above the latest closing price of 399.67 USD, suggesting that many analysts see upside potential over the coming 12 months if the company delivers on its guidance and maintains its margins.

Dividend, cash returns and peer context

UnitedHealth Group’s latest quarterly dividend stands at 2.32 USD per share, according to alerts compiled by MarketBeat. On an annualized basis, this corresponds to a total dividend of 9.28 USD per share, which at the recent share price of 399.67 USD translates into a dividend yield of around 2.3 percent. For long term investors, this combination of a moderate yield and regular growth in earnings guidance can be attractive, especially relative to certain peers in the global managed care sector.

Many European health insurers and diversified health care groups, such as those in the DAX and broader European indices, currently trade on comparable or slightly lower earnings multiples but with different growth and regulatory profiles. From a DACH investor perspective, UnitedHealth Group can serve as a benchmark for scale and profitability in global health care services, with its market capitalization of approximately 358.74 billion USD as of September 2, 2026 placing it among the largest health care companies worldwide. The sizeable revenue base of 112.03 billion USD in Q2 2026 and the consistent earnings beats over recent quarters make the stock a reference point when comparing valuation and growth within the sector.

UnitedHealthcare services as a revenue driver

The UnitedHealthcare segment is one of the main operating pillars of UnitedHealth Group and includes commercial, Medicare and Medicaid health benefit offerings to individuals and employer groups. While the latest MarketBeat summaries focus primarily on consolidated earnings and guidance, the underlying business is driven by the scale of beneficiaries and the efficiency of medical cost management. Historical reporting shows that UnitedHealthcare has been a major contributor to the group’s revenue base, with tens of millions of covered lives in the United States and a growing focus on value based care arrangements.

For investors evaluating UnitedHealth Group stock, the performance of UnitedHealthcare remains central: the segment’s ability to maintain underwriting discipline and manage medical costs directly affects the consolidated net margin, which MarketBeat notes stood at about 3.14 percent for the most recent quarter. Even small improvements in this margin can have significant effects on net income given the group’s revenue level of 112.03 billion USD in Q2 2026. In practical terms, a one percentage point improvement in net margin on that quarterly revenue base would represent more than 1 billion USD in additional quarterly profit, underscoring why segment level execution is closely watched.

Stock valuation and recent trading levels

Based on the latest closing data compiled by MarketBeat as of September 2, 2026, UnitedHealth Group stock closed at 399.67 USD on the New York Stock Exchange, giving the company a market capitalization of approximately 358.74 billion USD at that date. At this price, the shares are trading near 20 times the midpoint of the 2026 adjusted earnings guidance of 19.75 USD per share, which many market participants see as a reasonable valuation for a company with UnitedHealth’s earnings visibility and cash flow characteristics.

From a chart perspective, recent price data show the stock fluctuating around the 400 USD mark in late August and early September 2026, with short term performance indicators such as one month returns signaling a modest drawdown of about 4.5 percent over the period according to MarketBeat. This suggests that while the fundamental backdrop is robust, investor sentiment has been somewhat cautious in the near term, possibly reflecting broader market conditions or sector rotation rather than company specific concerns. For DACH based investors accessing the stock via international trading venues or derivative products, such price consolidation phases are often used to reassess entry points and portfolio weightings.

UnitedHealth Group at a glance

• Company: UnitedHealth Group Incorporated
• ISIN: US91324P1021
• Ticker: UNH
• Trading venue: NYSE
• Price (as of September 2, 2026): 399.67 USD
• Market capitalization: 358.74 billion USD (as of September 2, 2026)
• Sector / Industry: Health care / Managed care and health services
• Index membership: S and P 500